{
  "id": 1844906,
  "title": "Duopharma poised to benefit from healthcare reforms, patent cliff",
  "url": "https://urgent.news/2026/08/19/duopharma-poised-to-benefit-from-healthcare-reforms-patent-cliff",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-19T01:00:39.000Z",
  "source": {
    "name": "New Straits Times",
    "slug": "new-straits-times",
    "url": "https://www.nst.com.my/business/corporate/2026/08/1514191/duopharma-poised-benefit-healthcare-reforms-patent-cliff"
  },
  "original_language": "en",
  "account": "KUALA LUMPUR: Analysts at CIMB Securities Sdn Bhd believe Duopharma Biotech Bhd's long-term prospects remain solid due to ongoing healthcare reforms and a looming patent cliff for originator drugs in key therapeutic categories. The research firm cites a significant rise in Duopharma's second-quarter private sector sales volumes as evidence that its strategy of leveraging Malaysia's healthcare reform agenda is paying off, and should continue to drive earnings growth. Duopharma's second-quarter revenue increased by six percent year-on-year, mainly due to higher private sector sales, while sales to the public sector were bolstered by approved products purchase list supply agreements and human insulin supply contracts with the Health Ministry. Consequently, Duopharma's net profit rose 32 percent to RM30 million in the period, representing 57 percent of our earnings forecasts and 61 percent of the consensus full-year estimates. CIMB Securities explains this growth aligns with projections as the second half of the year typically sees weaker performance for the company. Long-term, the firm expects Duopharma's net profit to decline by 3.5 percent in 2026 due to a smaller human insulin contract, before growing by 3.6 percent in 2027 as private sector sales climb. CIMB Securities keeps its earnings estimates in line with expectations, retaining a \"Buy\" rating and target price of RM1.83 per share.",
  "summary": "KUALA LUMPUR: Duopharma Biotech Bhd's long-term prospects should remain supported by ongoing healthcare reforms and an impending patent cliff for originator drugs across major therapeutic areas, CIMB Securities Sdn Bhd said.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}